Bisdemethoxycurcumin-mediated Attenuation of Apoptosis Prevents Gentamicin-induced Ototoxicity in Mouse Cochlear UB/OC-2 Cells

In Vivo. 2022 May-Jun;36(3):1095-1105. doi: 10.21873/invivo.12807.

Abstract

Background/aim: Gentamicin has been widely prescribed since the last two decades despite its ototoxicity and nephrotoxicity. Bisdemethoxycurcumin (BDMC) is an affordable and safe curcuminoid with medicinal properties. We aimed to understand the effects of BDMC on the gentamicin-induced hair cell damage in mouse cochlear UB/OC-2 cells, in order to elucidate the therapeutic potential of BDMC against gentamicin-induced ototoxicity.

Materials and methods: We quantified the cell membrane potential and examined the regulators and cascade proteins in the intrinsic pathway of hair cell apoptosis. Mouse cochlear UB/OC-2 cells were treated with BDMC before exposure to gentamicin. The effects of BDMC on hair cell viability, mitochondrial function, and apoptosis-related proteins were examined by flow cytometry, western blot, and fluorescent staining.

Results: Our results revealed that BDMC reversed gentamicin-mediated cycle arrest at the G2/M phase, stabilizing the mitochondrial membrane potential, decreasing cleaved caspase proteins, and successfully reversing hair cell apoptosis.

Conclusion: BDMC is a potential agent for reducing gentamicin-induced ototoxicity.

Keywords: Gentamicin; apoptosis; bisdemethoxycurcumin; mitochondrial function; ototoxicity; reactive oxygen species.

MeSH terms

  • Animals
  • Apoptosis
  • Diarylheptanoids / pharmacology
  • Gentamicins* / toxicity
  • Mice
  • Ototoxicity* / drug therapy
  • Ototoxicity* / etiology
  • Ototoxicity* / prevention & control

Substances

  • Diarylheptanoids
  • Gentamicins
  • bisdemethoxycurcumin